Claudia D Baldus
Overview
Explore the profile of Claudia D Baldus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
3578
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stasik S, Eckardt J, Rollig C, Baldus C, Platzbecker U, Serve H, et al.
Br J Haematol
. 2025 Mar;
PMID: 40041934
IKZF1 mutations are recurrent alterations in acute myeloid leukaemia (AML), and hotspot point mutation, N159S, has recently been associated with unique gene expression and adverse risk. To better understand the...
2.
Huesmann J, Letsch A, Fransecky L, Spory L, Das Gupta D, Baldus C, et al.
Support Care Cancer
. 2025 Jan;
33(2):94.
PMID: 39805997
Background: Prior research indicates that engaging in physical activity during chemotherapy can positively influence both physical and psychological parameters in individuals with hematological neoplasms. However, the most effective type, level,...
3.
Recher C, Dumas P, Berard E, Tavitian S, Leguay T, Galtier J, et al.
Am J Hematol
. 2024 Nov;
100(1):23-32.
PMID: 39555737
According to current recommendations, older AML patients in first complete remission (CR) after induction chemotherapy should receive consolidation with intermediate-dose cytarabine (IDAC). However, no study has demonstrated the superiority of...
4.
Ruhnke L, Bill M, Zukunft S, Eckardt J, Schafer S, Stasik S, et al.
Blood Adv
. 2024 Nov;
PMID: 39504561
In 2022, the European LeukemiaNet (ELN) risk stratification for patients with AML has been updated. We aimed to validate the prognostic value of the 2022 ELN classification (ELN22) evaluating 1,570...
5.
Bendig S, Bufe S, Kotrova M, Fricke B, Proske C, Darzentas F, et al.
Br J Haematol
. 2024 Oct;
206(1):353-356.
PMID: 39449173
No abstract available.
6.
Rollig C, Steffen B, Schliemann C, Mikesch J, Alakel N, Herbst R, et al.
J Clin Oncol
. 2024 Sep;
43(1):65-74.
PMID: 39284116
Purpose: To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a once daily dose of 60...
7.
Baines J, Baldus C, Bertels F, Bruggemann M, Kaleta C, Laudes M, et al.
Evol Med Public Health
. 2024 Aug;
12(1):117-121.
PMID: 39114444
No abstract available.
8.
Mochmann L, Treue D, Bockmayr M, Silva P, Zasada C, Mastrobuoni G, et al.
Cancer Gene Ther
. 2024 Jun;
31(9):1344-1356.
PMID: 38851813
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by genomic aberrations in oncogenes, cytogenetic abnormalities, and an aberrant epigenetic landscape. Nearly 50% of AML cases will relapse with current...
9.
Neumann M, Beder T, Bastian L, Hanzelmann S, Bultmann M, Wolgast N, et al.
Leukemia
. 2024 May;
38(6):1213-1222.
PMID: 38744920
In contrast to B-cell precursor acute lymphoblastic leukemia (ALL), molecular subgroups are less well defined in T-lineage ALL. Comprehensive studies on molecular T-ALL subgroups have been predominantly performed in pediatric...
10.
Ravandi F, Subklewe M, Walter R, Vachhani P, Ossenkoppele G, Buecklein V, et al.
Leuk Lymphoma
. 2024 May;
65(9):1281-1291.
PMID: 38712673
AMG 330, a bispecific T-cell engager (BiTE®) that binds CD33 and CD3 on T cells facilitates T-cell-mediated cytotoxicity against CD33+ cells. This first-in-human, open-label, dose-escalation study evaluated the safety, pharmacokinetics,...